Edrani is a targeted therapy drug for chronic lymphocytic leukemia (CLL) and other types of lymphoma, belonging to the PI3K inhibitor class, particularly highly selective inhibitors targeting the PI3K delta subtype.

1、 Drug name

1. Common name: Idelalisib;

2. Product Name: Zydelig ®。

2、 Indications

1. Recurrent chronic lymphocytic leukemia (CLL): Combined with rituximab, suitable for patients with comorbidities who are only suitable for rituximab monotherapy.

2. Recurrent follicular B-cell non Hodgkin lymphoma (FL): suitable for patients who have received at least two systemic treatments.

3. Recurrent small lymphocytic lymphoma (SLL): suitable for patients who have received at least two systemic treatments.

3、 Specifications and characteristics

1. Specification: 150mg

2. Appearance: Tablets

4、 Main components

Active ingredient: Idelalisib, a PI3K δ kinase inhibitor.

5、 Usage and dosage

1. Recommended dosage: 150mg orally, twice daily.

2. Medication method: Take the whole tablet orally, before or after meals.

3. Missing service handling: If the missed service time is less than 6 hours, immediately make up for it; >Skip after 6 hours and take at the same time next time.

6、 Dose adjustment

Dose needs to be adjusted based on toxicity reactions:

1. Hepatotoxicity: Pause when ALT/AST>5-fold upper limit, and reduce to 100mg after recovery.

2. Diarrhea: Severe diarrhea should be paused or reduced.

3. Neutropenia: Pause when ANC<0.5Gi/L.

7、 Medication precautions

1. Monitoring requirements: Regular check of liver function and blood routine during treatment.

2. Diet: No special requirements.

3. Vomiting: If vomiting occurs after taking medication, there is no need to retake it. Take the next dose according to the plan.

8、 Medication for special populations

1. Pregnant women: Prohibited, may cause fetal malformation.

2. Breastfeeding period: Stop taking medication or breastfeeding.

3. Liver injury: Use with caution if baseline ALT/AST is greater than 2.5 times the upper limit.

9、 Adverse reactions

1. Common (≥ 20%): Diarrhea, fever, fatigue, cough, pneumonia, etc.

2. Serious reactions: hepatotoxicity, intestinal perforation, pneumonia, etc.

10、 Contraindications

It is contraindicated for individuals with severe allergies to Adelani (such as moderate toxicity epidermal necrolysis).

11、 Drug interactions

1. Avoid using strong CYP3A inducers (such as rifampicin) in combination.

2. Avoid using CYP3A substrates in combination (such as midazolam).

12、 Storage method

1. Storage temperature: 20-30 ° C (68-86 ° F).

2. Keep the original packaging and store it sealed.

Idelalisibinformation